trending Market Intelligence /marketintelligence/en/news-insights/trending/2Dq8Zh82ohOSneAmTSyvHw2 content esgSubNav
In This List

Natco launches generic to compete with Roche's influenza treatment

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Natco launches generic to compete with Roche's influenza treatment

India's Natco Pharma Ltd. launched a generic version of Roche Holding Ltd.'s Tamiflu in the U.S.

Alvogen partnered with Natco to market the influenza treatment, which is available in three doses.

Roche's Tamiflu had U.S. sales of approximately $403 million in the 12 months ending December 2015, according to IMS Health.